<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577443</url>
  </required_header>
  <id_info>
    <org_study_id>Adenosine H-20027630</org_study_id>
    <nct_id>NCT04577443</nct_id>
  </id_info>
  <brief_title>The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties.</brief_title>
  <official_title>To Investigate the Headache Induction and the Cerebral Hemodynamic Changes After Infusion of Adenosine in Healthy Volunteers and Migraine Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenosine is a nucleoside that plays a role in both vascular and nociceptive systems, and it&#xD;
      has been proposed that adenosine may cause headache in particularly sensitive subjects.&#xD;
&#xD;
      Thus, considerable evidence implied that adenosine plays a role in migraine pathophysiology,&#xD;
      it is still unknown if intravenous adenosine infusion provokes migraine attacks in healthy&#xD;
      subject or in migraine patients. Furthermore, adenosine's effects on the cerebral hemodynamic&#xD;
      remains unknown.&#xD;
&#xD;
      This study aims to clarify a possible coherence between adenosine and headache/migraine. In&#xD;
      general, the study will contribute to a greater understanding of migraine pathogenesis and&#xD;
      possibly lead to development of specific migraine treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence and change of migraine attack</measure>
    <time_frame>Before (-10 minutes) and after infusion (+12 hours) of adenosine compared with before and after infusion of saline</time_frame>
    <description>Occurrence and of migraine according to international criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cerebral hemodynamic</measure>
    <time_frame>Before (-10 minutes) and after infusion (+12 hours) of adenosine compared with before and after infusion of saline</time_frame>
    <description>Change on velocity of media cerebri artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and change of headache</measure>
    <time_frame>Before (-10 minutes) and after infusion (+12 hours) of adenosine compared with before and after infusion of saline</time_frame>
    <description>Occurrence of headache measured by numerical rating scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of diameter of the artery</measure>
    <time_frame>Before (-10 minutes) and after infusion (+12 hours) of adenosine compared with before and after infusion of saline</time_frame>
    <description>Change of diameter of superficial temporal artery and radial artery. The diameter will be measured by millimeter (mm).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Headache, Migraine</condition>
  <arm_group>
    <arm_group_label>Adenosine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients</description>
    <arm_group_label>Adenosine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Migraine patients without aura who fulfill criteria in the international&#xD;
             classification of headaches. This does not apply to healthy volunteers.&#xD;
&#xD;
          -  18-60 years.&#xD;
&#xD;
          -  50-90 kg.&#xD;
&#xD;
          -  Women of childbearing potential must use adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Headache less than 48 hours before the tests start&#xD;
&#xD;
          -  All primary headaches, except migraine without aura for migraine patients, according&#xD;
             to international classification of headache&#xD;
&#xD;
          -  Daily consumption of drugs of any kind other than oral contraceptives&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Cardiovascular disease of any kind, including cerebrovascular diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Messoud Ashina</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad Al-Karagholi</last_name>
    <phone>31191647</phone>
    <email>mahdi.alkaragholi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet-Glostrup</name>
      <address>
        <city>Glostrup</city>
        <state>Nordre Ringvej 57</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad A Al-Karagholi, MD</last_name>
      <phone>00 45 31 19 16 47</phone>
      <email>mahdi.alkaragholi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Song Guo, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Mohammad Al-Mahdi Al-Karagholi</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

